Program
Anti-c-Kit/MMAE Antibody-Drug Conjugate NN3201
Its studies are mostly in Gastrointestinal Stromal Tumors, led by Novelty Nobility.
Furthest: phase 1, since Jan 8, 20251 company-led study, 1 open or runningNext primary completion: Aug 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novelty Nobility | 11 open or running | phase 1since Jan 8, 2025 | Jan 8, 2025 | Aug 30, 2027phase 1 · NCT06805825 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 8, 2025First study: phase 1 study in Gastrointestinal Stromal TumorsFirst studyNCT06805825 · 67 planned · United States
Ahead
- Aug 30, 2027Primary completion: phase 1 study in Gastrointestinal Stromal TumorsNCT06805825
TargetBeta
KIT →read by rule
“An antibody-drug conjugate (ADC) composed of 2G4, a human monoclonal antibody directed against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), ”NCIt, by rule
Other programs on KIT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Avapritinibrule | Sanofi | phase 4 | 10 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| masitinibrule | AB Science | phase 3 | 38 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| ripretinibrule | Ono Pharmaceutical | phase 3 | 9 |
| velzatinib | GlaxoSmithKline | phase 3 | 8 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| elenestinib | Sanofi | phase 3 | 3 |
| NB-003rule | ningbo-newbay-technology-development-co-ltd | phase 3 | 2 |
| briquilimabrule | jasper-therapeutics-inc | phase 2 | 7 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06805825Gastrointestinal Stromal Tumors · United States | 1 | Recruiting | Aug 30, 2027 | 67 |
How it is read
Names in the registry
- “NN3201”, 1 entry
Conditions, from the studies’ own filings
- Gastrointestinal Stromal Tumors, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.